pI: 5.5454 |
Length (AA): 731 |
MW (Da): 81729 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There is 1 model calculated for this protein. More info on
this model, including the
model itself is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
10 | 731 | 3k1d (A) | 10 | 731 | 99.99 | 0 | 1 | 2.20149 | -1.24 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Dormant phase. | murphy |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Dormant phase. | hasan |
murphy | Identification of gene targets against dormant phase Mycobacterium tuberculosis infections. |
hasan | Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis. |
Ortholog group members (OG5_127579)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT2G36390 | 1,4-alpha-glucan branching enzyme 2-1 |
Arabidopsis thaliana | AT5G03650 | 1,4-alpha-glucan branching enzyme |
Brugia malayi | Bm1_02775 | 1,4-alpha-glucan branching enzyme |
Candida albicans | CaO19.13067 | likely glycogen branching enzyme |
Candida albicans | CaO19.5622 | likely glycogen branching enzyme |
Caenorhabditis elegans | CELE_T04A8.7 | Protein T04A8.7, isoform B |
Cryptosporidium hominis | Chro.60381 | 1,4-alpha-glucan branching enzyme |
Cryptosporidium parvum | cgd6_3280 | glycogen branching enzyme (1,4-alpha-glucan branching enzyme) |
Chlamydia trachomatis | CT_866 | 1,4-alpha-glucan branching enzyme |
Dictyostelium discoideum | DDB_G0274105 | 1,4-alpha-glucan branching enzyme |
Drosophila melanogaster | Dmel_CG33138 | 1,4-Alpha-Glucan Branching Enzyme |
Escherichia coli | b3432 | 1,4-alpha-glucan branching enzyme |
Echinococcus granulosus | EgrG_000239850 | glucan 14 alpha branching enzyme 1 |
Entamoeba histolytica | EHI_106090 | 1,4-alpha-glucan branching enzyme, putative |
Entamoeba histolytica | EHI_038160 | 1,4-alpha-glucan branching enzyme, putative |
Echinococcus multilocularis | EmuJ_000239850 | glucan (1,4 alpha), branching enzyme 1 |
Giardia lamblia | GL50803_15823 | 1,4-alpha-glucan branching enzyme |
Homo sapiens | ENSG00000114480 | glucan (1,4-alpha-), branching enzyme 1 |
Loa Loa (eye worm) | LOAG_06995 | hypothetical protein |
Mus musculus | ENSMUSG00000022707 | glucan (1,4-alpha-), branching enzyme 1 |
Mycobacterium tuberculosis | Rv1326c | 1,4-alpha-glucan branching enzyme GlgB (glycogen branching enzyme) |
Mycobacterium ulcerans | MUL_3936 | glycogen branching protein |
Neospora caninum | NCLIV_058980 | 1,4-alpha-glucan branching enzyme, putative |
Neospora caninum | NCLIV_004200 | hypothetical protein |
Oryza sativa | 4329532 | Os02g0528200 |
Oryza sativa | 4342117 | Os06g0726400 |
Saccharomyces cerevisiae | YEL011W | 1,4-alpha-glucan branching enzyme |
Schistosoma japonicum | Sjp_0065120 | ko:K00700 1,4-alpha-glucan branching enzyme [EC2.4.1.18], putative |
Schistosoma mansoni | Smp_094880 | starch branching enzyme II |
Schmidtea mediterranea | mk4.001372.07 | 1,4-alpha-glucan-branching enzyme |
Schmidtea mediterranea | mk4.001372.05 | |
Schmidtea mediterranea | mk4.001372.06 | |
Schmidtea mediterranea | mk4.001372.08 | 1,4-alpha-glucan-branching enzyme |
Schmidtea mediterranea | mk4.011524.03 | 1,4-alpha-glucan-branching enzyme |
Schmidtea mediterranea | mk4.005975.02 | 1,4-alpha-glucan-branching enzyme |
Toxoplasma gondii | TGME49_209960 | glycosyltransferase |
Toxoplasma gondii | TGME49_316520 | 1,4-alpha-glucan-branching enzyme |
Trichomonas vaginalis | TVAG_453180 | amylase, putative |
Trichomonas vaginalis | TVAG_276310 | starch branching enzyme II, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
mtu1349 this record | Mycobacterium tuberculosis | essential | nmpdr |
b3432 | Escherichia coli | non-essential | goodall |
CELE_T04A8.7 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_T04A8.7 | Caenorhabditis elegans | slow growth | wormbase |
TGME49_316520 | Toxoplasma gondii | Essentiality uncertain | sidik |
TGME49_209960 | Toxoplasma gondii | Essentiality uncertain | sidik |
TGME49_316520 | Toxoplasma gondii | Probably non-essential | sidik |
TGME49_209960 | Toxoplasma gondii | Probably non-essential | sidik |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.3
1 literature reference was collected for this gene.